News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Drug Helps Shrink Tumors in Rare Eye Cancer, Memorial Sloan-Kettering Cancer Center Study



6/3/2013 7:48:30 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology (ASCO). The findings are potentially practice-changing for a historically "untreatable disease." Though uveal melanoma is rare — there are only 2,500 cases diagnosed in the United States each year — about half of patients will develop metastatic disease, and survival for patients with advanced disease has held steady at nine months to a year for decades.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release
Read at EurekAlert!


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES